SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community debates the clinical trial trajectory of its lead candidate, GPS, alongside excitement surrounding the upcoming AACR presentation for its secondary asset, SLS009. Investors are actively tracking potential gamma squeeze dynamics and institutional positioning as they monitor the trial's survival data for signs of long-term efficacy.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as positive sentiment around Middle East stability and potential geopolitical breakthroughs fuels renewed market confidence, leading to a surge above key technical resistance levels. The community is actively discussing the impact of institutional buying, with many debating whether this move signals the beginning of a sustained breakout or a temporary bull trap amidst broader macroeconomic uncertainty.

Based is a financial superapp built on Hyperliquid that lets users trade crypto, equities, and commodities from a single interface, fund accounts directly from bank accounts or credit cards, and spend balances at over 100 million merchants worldwide using a Visa Platinum card that converts at the point of sale with no separate off-ramp required. The platform operates across web, iOS, Android, and desktop with one account, and includes features like curated Launchpools for early project access and AI-native wallets for autonomous trading and risk monitoring.

Based Token

BASED is seeing intense volatility as the community debates whether recent price swings are organic accumulation or a manipulated pump-and-dump scheme. Investors are actively discussing the token's utility as a crypto super app while expressing polarizing views on its sustainability amid heavy short-interest and high trading volume.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by strong technical indicators and anticipation surrounding upcoming clinical data presentations. The community is actively discussing the stock's significant upside potential, fueled by speculation regarding a possible buyout or partnership as the company approaches key regulatory milestones.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive expansion into AI infrastructure, including data center financing, against broader market concerns regarding the liquidity and default risks within its massive private credit portfolios. The community remains divided, with some betting on a long-term recovery driven by the firm's dominant scale and fee-bearing AUM, while others monitor for signs of potential systemic stress or regulatory hurdles impacting its real estate and credit divisions.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened interest as investors weigh the stock's role as a leveraged proxy for Bitcoin against concerns regarding corporate dilution and debt obligations. The community remains sharply divided, with bulls pointing to the company's aggressive Bitcoin acquisition strategy and potential legislative catalysts, while skeptics warn of unsustainable capital structures and the risks of a volatility-driven squeeze.

TOSHI

TOSHI is trending as community members debate its potential to lead the Base network ecosystem and spark a broader meme coin rally. Discussions are heavily focused on technical setups, community-driven accumulation, and speculation surrounding future institutional adoption or exchange listings.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing intense investor focus as the company gears up for earnings, with community discussions heavily centered on the potential for a short squeeze given the stock's elevated short interest and upcoming volatility. Traders are closely monitoring the company's recent strategic acquisitions and their ability to transition into commercial production, while broader sector synergy with AI-driven quantum hardware remains a key catalyst driving bullish sentiment.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is seeing aggressive call-buying activity and significant volume, with investors speculating on its potential transition into an AI and high-performance computing infrastructure player. While there is no official news regarding a hyperscaler partnership, market participants are actively positioning for a potential breakout, driven by the sector's broader correlation with data center energy demand.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is attracting attention as community members debate its potential for a supply-driven breakout, citing the token's limited circulating supply and the recent launch of the Legend app. Traders are closely monitoring governance updates and protocol developments, while the community remains divided between those viewing the current price as a generational buying opportunity and others concerned about competitive pressure in the DeFi sector.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iridian Asset Management LLC CT Sells 9,770 Shares of Axsome Therapeutics, Inc. $AXSM

Iridian Asset Management LLC CT lowered its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 11.7% during the fourth quarter, according to its most recent Form 13F...

UBS Group Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

UBS Group upped their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a "buy" rating in a research report on Friday...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports...

Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM

Element Squared LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and...

Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda

(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor...

Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM

Hennion & Walsh Asset Management Inc. cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 18.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,386 shares of the company's stock after selling 8,530 share...

Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Truist Financial

Truist Financial upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday...

Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock

Guggenheim increased their price objective on Axsome Therapeutics from $220.00 to $245.00 and gave the company a "buy" rating in a report on Wednesday...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Investors are closely tracking the April 30th decision deadline for Alzheimer’s agitation, betting on a swift approval outcome.

Patients and shareholders are discussing the ongoing real-world clinical success of the flagship drug in treating major depressive disorder.

Optimistic traders are modeling post-approval upside potential, with many eyeing targets between $230 and $300.

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AXSM News

AXSMAxsome Therapeutics Inc